Skip to main content

Table 2 Inclusion and exclusion criteria for XALIA

From: XALIA: rationale and design of a non-interventional study of rivaroxaban compared with standard therapy for initial and long-term anticoagulation in deep vein thrombosis

Inclusion Exclusion
Female or male patients who are ≥18 years of age Patients with acute symptomatic PE*
Diagnosis of acute DVT, objectively confirmed Other exclusion criteria are dependent on local product information
Indication for anticoagulation therapy for at least 12 weeks
Patients willing to participate in the study and available for follow-up
  1. *A parallel symptomatic PE is not an exclusion criterion; however, XALIA will not enrol patients with only PE.
  2. DVT, deep vein thrombosis; PE, pulmonary embolism.